


U.S. Application Serial No. 09/200,743

a<sup>1</sup>  
cont

wherein R represents an alkyl or alkynyl group having 1-4 carbon atoms, [or] a substituted or unsubstituted phenyl group [optionally substituted by] wherein the substituents are selected from the group consisting of [C<sub>1-4</sub>] C<sub>1</sub>-C<sub>4</sub> alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl, [or] methylenedioxy, and combinations thereof, or [represents] a tetrahydronaphthyl group;

R<sup>1</sup> represents hydrogen, trifluoro [(C<sub>1-4</sub>)] (C<sub>1</sub>-C<sub>4</sub>) alkyl, alkyl, or alkynyl;

X represents hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl [having 1-4 carbon atoms], alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio, or alkoxy [aralkoxy]; and


R<sup>2</sup> represents a C<sub>1</sub> - C<sub>10</sub> alkyl group or a substituted or unsubstituted phenyl group [optionally substituted by one or more of the following groups] wherein the substituents are selected from the group consisting of C<sub>1</sub> - C<sub>10</sub> alkyl, [a] halogen [group], [a] nitro [group], hydroxy [group], [and/or] alkoxy [group], and combinations thereof;

U.S. Application Serial No. 09/200,743

*R<sup>1</sup> contd*

with the proviso that when X is fluorine in the 4-position of the phenyl ring and R<sup>1</sup> is

hydrogen, then R is not



Claim 2

Line 1, change "Compound" to --The compound--

Line 2, change "the 3,4" to --a 3,4--.

Line 4, after the formula, insert --- (a period).

Claim 3

Line 1, change "Compound" to --The compound--; delete "or 2"

Line 2, delete "preferably".

Claim 4

Line 1, change "Compound" to --The compound--; change "claim 1-3," to --claim 1,--

Line 2, change "C1-C4" to --C<sub>1</sub>-C<sub>4</sub>--.

U.S. Application Serial No. 09/200,743

Claim 5

Line 1, change "Compound" to --The compound--; change "claims 1-4," to

--claim 1,--

Line 2, change "C1-C2" to --C<sub>1</sub>-C<sub>2</sub>--.Claim 6

Line 1, change "Compound" to --The compound--; change "any of the previous claims" to

--claim 1,--

Claim 7


Line 1, change "Compound" to --The compound--

Lines 2-3, delete ", preferably at least 500 and most preferably of at least 1000";


Line 3, after "per ml" insert --at about 20°C--

a<sup>2</sup>

Claim 8 (amended). A process [Process] for preparing a compound according to [any of the previous claims] claim 1, comprising the steps of mixing together a compound, a salt, and/or a base thereof, having the formula II:



U.S. Application Serial No. 09/200,743



wherein [:] R represents an alkyl or alkynyl group having 1-4 carbon atoms, [or] a substituted or unsubstituted phenyl group [optionally substituted by] wherein the substituents are selected from the group consisting of [C<sub>1-4</sub>] C<sub>1</sub>-C<sub>4</sub> alkyl, alkylthio, alkoxy, halogen, nitro, acylamino, methylsulfonyl, [or] methylenedioxy, and combinations thereof, or [represents] a tetrahydronaphthyl group;[.]


R<sup>1</sup> represents hydrogen, trifluoro [(C<sub>1-4</sub>)] (C<sub>1</sub>-C<sub>4</sub>) alkyl, alkyl, or alkynyl;[.]

X represents hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl [having 1-4 carbon atoms], alkoxy, trifluoroalkyl, hydroxy, halogen, methylthio, or aralkyloxy; [aralkoxy,]

and with the proviso that when X is fluorine in the 4-position of the phenyl ring and R<sup>1</sup> is hydrogen, then R is not

A<sup>2</sup>  
cont

U.S. Application Serial No. 09/200,743



, with a sulfonic acid of the general formula  $R^2-SO_3H$ , wherein

$R^2$  represents  $C_1 - C_{10}$  alkyl group[,] or a substituted or unsubstituted phenyl group  
[optionally substituted by one or more of the following groups] wherein the substituents  
are selected from the group consisting of  $C_1 - C_{10}$  alkyl, [a] halogen [group], [a] nitro  
[group], hydroxy [group], [and/or] alkoxy [group], and combinations thereof.  
[to form a solution, whereafter the solid formed may be separated.]

Claim 9

Line 1, change "Compound" to --The compound--, delete "according to any of the  
claims 1-7"

Line 2, change "obtainable" to --produced--.

A<sup>3</sup>  
Claim 11 (amended). A pharmaceutical composition [Medicament] comprising a  
pharmaceutically effective amount of a compound according to [any of the claims 1-7, 9, 10]  
claim 1 and at least one pharmaceutically acceptable carrier or diluent [carriers/diluents].

U.S. Application Serial No. 09/200,743

Claim 15

Line 1, Change "Process" to --A process--

Lines 1-2, delete "ion or solvate"

Line 3, Change "any of the claims 1-7, 9 and 10" to --claim 1--

Line 4, delete "essentially"

Line 10, after "methanol" insert --, and.

a<sup>4</sup>

Claim 17 (amended). The process according to claim 15, wherein the salt produced is recovered as a solid [Salt according to claim 16,] having a purity of at least 90 wt%[, preferably at least 95 wt% and most preferably at least 98%]

a<sup>5</sup>

Claim 20 (amended). A process [Process] for providing a free base comprising the step of mixing together a compound according to [any of the claims 1-7, 9, 10,] claim 1 with an organic base, [and/or] inorganic base, or mixture thereof.

Claim 21

Line 1, Change "Process" to --The process--

Line 2, delete "essentially"

a<sup>6</sup>

Claim 22 (amended). The [A free base obtainable by the] process according to claim 20, further comprising isolating said free base [having] in a purity of at least 95%.


U.S. Application Serial No. 09/200,743

Please add the following new claims:

a<sup>1</sup> --24. The compound according to claim 1, wherein R<sup>1</sup> represents trifluoro (C<sub>1</sub>-C<sub>4</sub>) alkyl, alkyl or alkynyl.

25. The compound according to claim 1, wherein R represents a substituted or unsubstituted phenyl group.

26. The compound according to claim 1, wherein X is fluorine in the 4-position of the phenyl ring, R<sup>1</sup> is alkyl, and R is



27. A method for treating depression, obsessive/compulsive disorders, panic disorders, bulimia, anorexia, pain, obesity, senile dementia, migraine, or social phobias, which comprises administering to a patient in need thereof an effective amount of the compound as claimed in claim 1.

28. The method according to claim 27, wherein said patient is a human.

29. The method according to claim 27, wherein said method comprises administering